PROSER2

Across TCGA pan-cancer cohorts, PROSER2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PROSER2 data layer compared with 22 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PROSER2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated PROSER2 expression acts as an unfavorable survival marker.

PDAC, GBM, and LUAD are the cancer types where PROSER2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	II,III,IV	0.276	0.543	.013	7	view →
GBM	DFS	Median	All	0.663	0.908	.020	4	view →
LUAD	DFS	Median	III,IV	0.432	0.925	.047	3	view →
CCRCC	DFS	Tertile	III,IV	0.806	1.000	.030	2	view →
LSCC	OS	Median	II,III,IV	0.903	1.000	.021	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PROSER2–PDAC (OS)

Open the PDAC breakdown →